This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelley, M. J. Articles by Bergan, R. C. Search for Related Content PubMed PubMed Citation Articles by Kelley, M. J. Articles by Bergan, R. C.

Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers

¹ Department of Medicine, Duke University and Durham Veterans Affairs Hospital, Durham, North Carolina; ² Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland; ³ Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York; ⁴ University of Minnesota, Minneapolis, Minnesota; and ⁵ Division of Hematology/Oncology, Department of Medicine Northwestern University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois

Requests for reprints: Michael J. Kelley, Duke University/Veterans Affairs Hospital, Hematology/Oncology (111G), 508 Fulton Street, Durham, NC 27705. Phone: 919-286-0411, ext. 7326; Fax: 919-286-6824. E-mail: kelleym{at}duke.edu

Cigarette smoking is thought to contribute to carcinogenesis by formation of DNA adducts of tobacco smoke constituents leading to genotoxic damage. The dithiolethione, oltipraz, is a putative cancer chemopreventive agent that induces phase II detoxifying enzymes in preclinical models and reduces aflatoxin adducts in humans living in areas with high dietary levels. To determine if oltipraz could reduce adduct levels of tobacco smoke constituents in the lungs and other target organs, chronic smokers were enrolled to one of three arms: 400 or 200 mg/wk oral oltipraz or placebo. Endobronchial tissue and bronchoalveolar lavage were done before and after 12 weeks of drug treatment; peripheral blood, urine, and oral saline rinse were also collected. Toxicity was assessed every 4 weeks. Fifty-nine of the 77 enrolled subjects completed the study. Of those receiving oltipraz, 15% experienced grade 2/3 toxicity, which was predominantly gastrointestinal. All subject withdrawals occurred in the oltipraz groups. There was no significant difference between pre- and post-polycyclic aromatic hydrocarbon-DNA adduct levels in lung epithelial cells measured by immunoperoxidase staining between treatment and placebo groups. Likewise, no significant differences were found in polycyclic aromatic hydrocarbon or benzo(a)pyrene-7,8-diol-9,10-epoxide adducts measured in blood, oral lining cells, or bladder lining cells. There was also no increase in mRNA or enzymatic activity of phase II enzymes and no change in glutathione levels. Thus, despite moderate drug-related toxicity, there was no significant effect on pharmacodynamic or surrogate risk biomarkers. Other agents with lower toxicity and greater activity to induce phase II enzymes are needed to definitively test the detoxification-induction paradigm in smokers.

This article has been cited by other articles:

				Y. Zhang and R. Munday Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther., November 1, 2008; 7(11): 3470 - 3479. [Abstract] [Full Text] [PDF]

				L. Zhou, Y. Jiang, A. Tan, A. R. Greenlee, Y. Shen, L. Liu, and Q. Yang Silencing of N-Ras Gene Expression Using shRNA Decreases Transformation Efficiency and Tumor Growth in Transformed Cells Induced by Anti-BPDE Toxicol. Sci., October 1, 2008; 105(2): 286 - 294. [Abstract] [Full Text] [PDF]

				P. Vineis and F. Perera Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 547 - 567. [Abstract] [Full Text] [PDF]

				M. Lakshman, L. Xu, V. Ananthanarayanan, J. Cooper, C. H. Takimoto, I. Helenowski, J. C. Pelling, and R. C. Bergan Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice Cancer Res., March 15, 2008; 68(6): 2024 - 2032. [Abstract] [Full Text] [PDF]

				P. Vineis and F. Perera Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1954 - 1965. [Abstract] [Full Text] [PDF]

				T. W. Kensler, J.-G. Chen, P. A. Egner, J. W. Fahey, L. P. Jacobson, K. K. Stephenson, L. Ye, J. L. Coady, J.-B. Wang, Y. Wu, et al. Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in a Randomized Clinical Trial in He Zuo Township, Qidong, People's Republic of China Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2605 - 2613. [Abstract] [Full Text] [PDF]